eIF6 is potential diagnostic and prognostic biomarker that associated with ¹⁸F-FDG PET/CT features and immune signatures in esophageal carcinoma

Yan Gao†, Lingling Yuan†, Jing Zeng†, Fuyan Li†, Xiaohui Li†, Fan Tan†, Xusheng Liu†, Huabing Wan†, Xueyan Kui†, Xiaoyu Liu†, Changbin Ke* and Zhijun Pei†,2*

Abstract

Background: Although eukaryotic initiation factor 6 (eIF6) is a novel therapeutic target, data on its importance in the development of esophageal carcinoma (ESCA) remains limited. This study evaluated the correlation between eIF6 expression and metabolic analysis using fluorine-18 fluorodeoxyglucose (¹⁸F-FDG) -Positron emission tomography (PET) and immune gene signatures in ESCA.

Methods: This study employed The Cancer Genome Atlas (TCGA) to analyze the expression and prognostic value of eIF6, as well as its relationship with the immune gene signatures in ESCA patients. The qRT-PCR and Western blot analyses were used to profile the expression of eIF6 in ESCA tissues and different ESCA cell lines. The expression of tumor eIF6 and glucose transporter 1 (GLUT1) was examined using immunohistochemical tools in fifty-two ESCA patients undergoing routine ¹⁸F-FDG PET/CT before surgery. In addition, the cellular responses to eIF6 knockdown in human ESCA cells were assessed via the MTS, EdU, flow cytometry and wound healing assays.

Results: Our data demonstrated that compared with the normal esophageal tissues, eIF6 expression was upregulated in ESCA tumor tissues and showed a high diagnostic value with an area under curve of 0.825 for predicting ESCA. High eIF6 expression was significantly correlated with shorter overall survival of patients with esophagus adenocarcinoma (p = 0.038), but not in squamous cell carcinoma of the esophagus (p = 0.078). In addition, tumor eIF6 was significantly associated with ¹⁸F-FDG PET/CT parameters: maximal and mean standardized uptake values (SUVmax and SUVmean) and total lesion glycolysis (TLG) (rho = 0.458, 0.460, and 0.300, respectively, p < 0.01) as well as GLUT1 expression (rho = 0.453, p < 0.001). A SUVmax cutoff of 18.2 led to prediction of tumor eIF6 expression with an accuracy of 0.755. Functional analysis studies demonstrated that knockdown of eIF6 inhibited ESCA cell growth and migration, and fueled cell apoptosis. Moreover, the Bulk RNA gene analysis revealed a significant inverse association...
between eIF6 and the tumor-infiltrating immune cells (macrophages, T cells, or Th1 cells) and immunomodulators in the ESCA microenvironment.

**Conclusion:** Our study suggested that eIF6 might serve as a potential prognostic biomarker associated with metabolic variability and immune gene signatures in ESCA tumor microenvironment.

**Keywords:** eIF6, Esophageal carcinoma, \(^{18}F\)-FDG-PET parameter, GLUT1, Immune signatures, Prognostic biomarker

**Introduction**

Esophageal carcinoma (ESCA) is a common type of malignant tumors, which is divided into two main subtypes: esophageal squamous cell carcinoma (ESCC) which accounts for 90% of the ESCA, while the remaining is esophageal adenocarcinoma (EA) [1]. Due to lack of specific treatment for ESCC and methods for its early diagnosis, five-year survival rate remain below 15% [2]. \(^{18}F\)-fluorodeoxyglucose positron emission tomography (\(^{18}F\)-FDG PET/CT) is a noninvasive and preferred early diagnostic tool, which is widely employed in the assessment of response to therapy, by simultaneous assessment of tumor morphology and metabolism over time [3]. Tumor FDG uptake is determined by the expression of glucose transporter family (GLUT1, 3 and 4) and glycolytic enzymes [4]. The PET-related parameters include the maximal and mean standardized uptake values (SUVmax and SUVmean), metabolic tumor volume (MTV), and total lesion glycolysis (TLG), which correlates with biological factors in the tumor microenvironment (TME) [5, 6]. Significant correlation was found between PET imaging parameters and the in vivo biological characterization of cancer lesions [7–9]. Our previous data also demonstrated that \(^{18}F\)-FDG PET/CT parameters have important clinical value in predicting novel molecular and clinical phenotypes of malignant tumors. The phenotypes include nucleophosmin 1 (NPM1) expression in lung cancer [10], eukaryotic translation initiation factor 2 Subunit \(\beta\) (eIF2S2) expression in colorectal cancer [11], and methyltransferase 3 (METTL3) expression in ESCA [12].

Eukaryotic initiation factor 6 (eIF6) is the first eIF associated with large 60S subunit in the nucleus, which is involved in translation initiation [13–15]. Previous studies demonstrated that eIF6 is highly expressed in human cancers such as colorectal cancer; hepatocellular carcinoma, ovarian serous carcinoma, acute promyelocytic leukemia, non-small cell lung cancer, and affect lymphoma genesis and tumor progression [16–20]. In addition, eIF6 translational activity regulate fatty acid synthesis and glycolysis through upregulation of lipogenic and glycolytic enzymes [21]. Scagliola et al. [22] showed that eIF6 induces a metabolic rewiring during progression from non-alcoholic fatty liver to hepatocellular carcinoma. However, the functions and molecular mechanisms of eIF6 in ESCA remain unclear. FDG uptake reflects glucose metabolism in malignant cells [6]. This study evaluated the relationship between eIF6 expression and glucose metabolism using FDG-PET and examined the prognostic significance in ESCA patients.

Both metabolic and immune-mediated syndrome in the TME have been associated with malignant tumor progression and metastasis [23, 24]. Recent studies have shown that there is overexpression of eIF6 mRNA in activated T cells and lymphoid cells [16, 25]. Besides, eIF6 was shown to be essential in overall immune system, particularly for metabolic switch in CD4\(^+\) T cell activation [26]. On the other hand, potential of immune checkpoint inhibition (ICI), such as blockage of programmed cell death-1 (PD-1)/ PD-1 ligand 1 (PD-L1) pathway, has been established in several tumors [27, 28]. However, this treatment option has not been applied to all patients, thus the need to find new targets.

In this study, we correlated the eIF6 expression with patient survival using public database [29], as well as \(^{18}F\)-FDG PET parameters in ESCA patients. We then used ESCA cell lines to elucidate the functions of eIF6. In addition, we attempted to investigate the association between the eIF6 expression and gene signatures of immune cells in ESCA. Our data showed that eIF6 might be a potential diagnostic and prognostic biomarker in ESCA patients.

**Materials and methods**

**Patient samples**

The study respectively reviewed fifty-five patients who were surgically treated and had pathologically confirmed ESCC in Taihe Hospital from January 2018 to July 2020. This study included patients who underwent \(^{18}F\)-FDG PET/CT imaging and were analyzed using immunohistochemistry (IHC) tests. The patients had available clinicopathological data, and none of them received chemoradiotherapy prior to the \(^{18}F\)-FDG PET/CT imaging. In this study, we used thirteen paired surgically obtained samples from patients with ESCA. The fresh-frozen ESCA tissues and matched non-tumor tissues were analyzed by qRT-PCR and Western blot.

**\(^{18}F\)-FDG PET/CT imaging and data analysis**

Glucose metabolism was assessed by \(^{18}F\)-FDG PET/CT imaging using the Biograph mCT (64) system (Siemens
Healthcare, Germany). As described [10, 12], the patients fasted for at least 6 h but had free access to water until the start of the imaging process. Whole-body position was monitored 50 min after intravenous administration of FDG (3.7–4.1 MBq/kg) and lasted for about 15 min. The PET/CT images were acquired following the manufacturer’s protocol. The metabolic parameters of the $^{18}$F-FDG PET images were evaluated by two experienced nuclear medicine physicians who were blinded to the final clinical diagnosis. Briefly, a region of interest (ROI) was placed around the primary tumor, and then FDG uptake in the lesions was determined from the PET images to calculate the maximum and mean SUV ($SUV_{\text{max}}$ and $SUV_{\text{mean}}$). SUV is defined as tissue concentration (Bq/g) × lean body mass (g)/injected dose (MBq). A $SUV_{\text{max}}$ threshold of 2.5 was used to define the metabolic tumor volume (MTV) (cm$^3$), while total lesion glycolysis (TLG) is obtained by multiplying $SUV_{\text{mean}}$ by MTV (TLG = $\Sigma$MTV × $SUV_{\text{mean}}$) [30, 31]. In addition, the MTV and TLG were defined semi-automatically using an SUV-based platform as previously described [12].

**Quantitative real time PCR**
Total RNA was isolated from frozen tissues and cell lines using TRIzol reagent (Thermo Fisher Scientific, USA). The RNA was used to synthesize cDNA with RT Master Mix kit (TaKara, China). The qRT-PCR experiment was performed using a TB Green Premix Ex Taq Kit (TaKara, China). The qRT-PCR experiment was performed using a TB Green Premix Ex Taq Kit (TaKara, China) in the Applied Biosystems ViiA TM 7 Real-time PCR system (Life Technologies, CA). We used β-actin as an internal control for normalization. The following primers were used:

elf6, Forward: 5'-GGCGCACCAGGTGCTAGT AGG-3'; Reverse: 5'-CACAC-CAGTCATCCACC ACCATCC-3'.

β-actin, Forward: 5'-TCTTCCAGCCTTCCTCC T-3'; Reverse: 5'- AGCACTG-TGTTGGCGTACAG -3'.

**Western blot**
As previously described [19], fresh tissues or cells were collected and digested with RIPA buffer containing 1% protease inhibitor on ice. The protein concentrations were measured by BCA method (Beyotime Biotechnology) and then resolved in SDS-PAGE gel. The protein samples were transferred onto PVDF membranes (Millipore, USA), followed by incubation with primary antibodies; anti-elf6 (Thermofisher, Waltham, MA, USA), anti-GLUT1 (Abcam, Cambridge, UK), anti-Ecadherin (BD Pharmigen, USA), anti-Vimentin (Abcam), anti-Cytochrome c (Cyt c, Abcam), anti-CD45 (Proteintech, China), anti-CD11b (Abcam), anti-PD-L1 (Proteintech) or anti-GAPDH (Cell Signaling Technology, USA) at 4 °C overnight. The membranes were washed with TBST, and then incubated with secondary antibodies (Cell Signaling Technology, USA) for 1 h at room temperature. Finally, the proteins were visualized by an enhanced chemiluminescence (ECL) detection kit.

**Immunohistochemical (IHC) assay**
IHC staining was performed following a previously described protocol [10]. Briefly, the samples were dissected on 5-μm-thick tissue sections embedded in paraffin, and then incubated with antibodies against elf6 (1:400), GLUT1 (1:200), followed by secondary antibodies. Two pathologists who were blinded to clinical data independently analyzed the IHC data. The protein expression was profiled based on the staining intensity score, from 0 (negative), 1+ (weakly positive), 2+ (moderately positive) to 3+ (strongly positive). High- or low-expression was defined with scores equal to or above, and below the final IHC staining score 2, respectively.

**Gene expression pattern and patient prognosis in public datasets**
We downloaded the mRNA expression (HTSeq counts) and associated clinical data for different human cancers from the TCGA (https://portal.gdc.cancer.gov/). The expression profiles were plotted in the ggplot2 R (https://github.com/tidyverse/ggplot2). On the other hand, survival curve was demonstrated using Kaplan–Meier plots [32]. To evaluate the predictive accuracy of elf6 in TCGA cancers, “pROC” in R package was used to generate the time-dependent receiver operating characteristic (ROC) curve and then the area under curve (AUC) was calculated.

**Enrichment analysis and functional networks in ESCA**
The elf6 co-expression genes in the TCGA-ESCA were analyzed by DESeq2 R package. We then performed correlation analysis of the different variables using the Spearman’s or Pearson’s correlation test and Fisher’s exact test. Gene ontology (GO) biological process and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis were performed using the clusterProfiler in R package (p.adj<0.1 & qvalue<0.2). Thereafter, top 200 protein coding genes significantly correlated with elf6 were screened out for construction of PPI networks. Each network node was determined and visualized with Cytoscape. The top 10 genes with most connections were selected and considered to be ‘hub’ genes.

Next, the TCGA-ESCA samples were classified into two groups based on the elf6A expression status. The edgeR
package in Bioconductor was used to define differentially expressed genes (DEGs) between the eIF6 high and low ESCA samples ($|\log2FC|>1.5$, $p$ value $<0.05$). In addition, we used the GSEA to investigate meaningful biological processes. The hallmark gene sets and glycolysis signatures (REACTOME_GLYCOLYSIS, KEGG_GLYCOLYSIS_GKCYCIBEIGENES, and HALLMARK_GLYCOLYSIS) were downloaded from the Molecular Signatures Database (MSigDB). The false discovery rate (FDR) cutoff of 0.25, and an adjusted $p$ $<0.05$ were considered significance. Besides, 282 glycolytic genes in three glycolysis signatures were downloaded from the MSigDB database. Pearson correlation coefficients of the eIF6 expression and glycolytic genes were calculated using TIMER database and DESeq2 R package in the TCGA database.

**Cell culture and transfection**

Human epithelial cell line (HET1A cells) and ESCA cell lines (Eca109, KYSE30, KYSE150, CEC2) were obtained from the Cell Bank of Chinese Academy of Sciences (Shanghai, China). The cells were transfected with eIF6 siRNA using Lipofectamine 8000 transfection reagent (Beyotime, China), following the manufacturer’s instructions. The target sequences were: 5’-CTG CTT TGC CAA GCT CAC CAA-3’ for siRNA-1 (sieIF6-1) and 5’-CTG GTG CAT CCC AAG ACT TCA-3’ for siRNA-2 (sieIF6-2).

**Cell viability analysis using MTS assay and EdU proliferation assay**

The ESCA cells were seeded into 96-well plates and transfected with siRNA. After transfection for 0, 24, 48 or 72 h, we added MTS (CellTiter 96 Aqueous One Solution Cell Proliferation Assay, Promega) to each well and then incubated for 2 h. The optical density (OD) was then measured at 490 nm using a microplate reader (SpectraMax M3). Another proliferation assay was performed with the usage of an EdU kit (ClickTM, EDU 488, Beyotime) according to the manufacturers instruction. In brief, the transfected cells were incubated with diluted EdU (10 uM) for 2 h. Subsequently, cells were fixed and stained by Click Reaction Mixture and DAPI. Images were captured from five random fields under a fluorescent microscope. Finally, percentage of EdU positive cells was quantitated using Image J software.

**Flow cytometry analysis of apoptosis**

Cell apoptosis was quantified by an Annexin V-FITC Apoptosis Detection Kit (BD Pharmigen, USA). The treated cells were harvested and washed twice with PBS. Afterwards, the cells were resuspended and then 3 µl FITC-conjugated annexin V and 10 µl propidium iodide staining solution were added. The rate of apoptosis was immediately measured using a FACS Calibur flow cytometer (BD Bioscience, USA).

**Wound healing assay**

The cells were plated overnight and scratched by a 10 µL pipette tip. Subsequently, the cells were washed with sterile PBS and then refilled with complete medium. After transfection with siRNA, the wounded cells were analyzed every day by a microscope and then analyzed using Image J software.

**Estimation of immune cell characteristics**

TCGA-ESCA patients were classified into low-expression or high-expression group based on the eIF6 expression. The xCell in R package was employed to evaluate immune and stroma cell abundance in the two groups. The relative immune signature score was estimated using the R GSVA package [33, 34]. In addition, the Tumor Immune System Interactions (TISIDB) database was used to study immune-related gens and immune subtypes, based on the eIF6 expression [35]. On the other hand, the Tumor Immune Estimation Resource (TIMER, https://cistrome.shinyapps.io/timer/) was used to define the correlation using the spearman correlation coefficient of a pair of genes and then estimated statistical significance, as well as tumor purity in ESCA. In addition, the correlation between the eIF6 expression and different immune signatures in ESCA samples in the GEPIA2 databases (http://gepia2.cancer-pku.cn) was calculated using Pearson’s correlation test.

**Statistical analysis**

SPSS package (version 16.0, SPSS for Windows, 2007) and R package version (4.0.3) were used for statistical analyses. A $p$ $<0.05$ was used to define statistical significance. In this study, the survival and ROC analysis were carried out in R or corresponding R packages which included survival, survminer and pROC. For bivariate analysis, $\chi^2$ test, $\chi^2$ test or Fisher’s exact test were used. Spearman’s rho test was used to evaluate the correlation between the PET parameters and eIF6 expression levels in the ESCA patients. In addition, we used the greatest Youden index (sensitivity + specificity – 1) to define optimal cutoff value for the ROC curve. The T-test and Wilcoxon tests were used to compare differences between two groups, while comparisons among multiple groups were performed using the Tukey and the Wilcoxon tests. Statistical analysis and visualization were performed using the R Statistical Package and ggplot2 package.
Results
Upregulation of eIF6 is associated with ESCA patient prognosis
The eIF6 mRNA expression was analyzed in pan cancers in the TCGA database. The data demonstrated significantly higher expression of eIF6 mRNA in several cancer types, including bladder, breast, colorectal, ESCA, head and neck squamous cell, liver, lung, pancreatic, stomach, thyroid, and uterine corpus endometrial cancers, compared with normal tissues, while lower expression was observed in kidney cancer (Fig. 1A). In addition, a higher level of eIF6 expression was observed in ESCA and EA compared to normal tissues in the TCGA cohort (Fig. 1B). Thereafter, the eIF6 expression pattern was validated by qRT-PCR (Fig. 1C) and Western blot analyses (Fig. 1D) in fresh paired ESCC and adjacent patient
tissues. Our data showed that eIF6 was significantly upregulated in ESCC tissues. We then performed IHC analysis in fifty-two patients and showed that the tumor tissues had higher expression of eIF6 compared with normal epithelia tissues (p < 0.05, Fig. 1E, F).

The 52 ESCC patients were divided into the eIF6-low (n = 35) and eIF6-high (n = 17) expression group. Subsequent analyses revealed that there was significant correlation between the eIF6 expression and SUV\textsubscript{max} (p = 0.010) or SUV\textsubscript{mean} (p = 0.018), but not with gender, age, differential status, lymph node metastasis, p stage, TLG or MTV (Table 1). Finally, the ROC curve analyses demonstrated that eIF6 displayed superior diagnostic accuracy (AUC = 0.825, 95% CI, 0.662–0.988) which could distinguish the ESCA patients from healthy controls (Fig. 1G). Notably, higher eIF6 expression was negatively associated with survival time of patients with EA (n = 80, p = 0.038), but not with ESCC Kaplan-murrier plot (n = 81, p = 0.078) (Fig. 1H, I).

Metabolic pathway enrichment analysis of eIF6 in ESCA
To evaluate the biological interaction network and related signaling pathways associated with eIF6, the top 10 genes most positively or negatively correlated with eIF6 were analyzed in the heat map (Fig. 2A). ESCA eIF6 expression was positively correlated with ROMO1 expression (r = 0.64, p = 3.53E−20), but negatively associated with AL021368.2 (r = −0.50, p = 1.16E−11). Our enriched GO terms analysis demonstrated that the genes that encode proteins correlated with eIF6 might be participating in membrane depolarization during action potential, constitute the extracellular structural matrix, alpha-actin in binding, and ion channel binding processes. The KEGG enrichment analysis showed that eIF6 is involved in cGMP-PKG signaling and platelet activation pathways (Fig. 2B). In addition, to identify top hub genes, we constructed a protein–protein interaction (PPI) network and showed that RPS21 and PSMA7 play key roles (Fig. 2C). On the other hand, a total of 2814 DEGs were screened upon eIF6 expression in 181 ESCA patients (Fig. 2D). GSEA was used to perform hallmark analysis for eIF6 and showed that most significant pathways in high-eIF6 group included HALLMARK\_MYC\_TARGETS (NES = 3.05, p.adjust = 0.017) and HALLMARK\_OXIDATIVE\_PHOSPHORYLATION (NES = 2.97, p.adjust = 0.018) (Fig. 2E). In addition, the functional analyses showed that glycolytic pathways such as KEGG\_GLYCOLYSIS\_GKYCIBEIGENES

### Table 1 Clinicopathological characteristics of 52 patients

| Variables                  | eIF6—low (N, %) | eIF6—high (N, %) | p     |
|----------------------------|-----------------|------------------|-------|
| Total                      | 35 (67.3%)      | 17 (32.7%)       |       |
| Clinical parameters        |                 |                  |       |
| Gender                     |                 |                  | 1.000 |
| Male                       | 28 (53.8%)      | 14 (26.9%)       |       |
| Female                     | 7 (13.5%)       | 3 (5.8%)         |       |
| Age (years)                |                 |                  | 0.854 |
| < 60                       | 21 (40.4%)      | 9 (17.3%)        |       |
| ≥ 60                       | 14 (26.9%)      | 8 (15.4%)        |       |
| Differential               |                 |                  | 0.662 |
| Poorly                     | 14 (26.9%)      | 5 (9.6%)         |       |
| High/Moderately            | 21 (40.4%)      | 12 (23.1%)       |       |
| Lymph node metastasis      |                 |                  | 1.000 |
| Negative                   | 20 (38.5%)      | 9 (17.3%)        |       |
| Positive                   | 15 (28.8%)      | 8 (15.4%)        |       |
| p Stage                    |                 |                  | 0.098 |
| 1                          | 12 (23.1%)      | 1 (1.9%)         |       |
| 2                          | 5 (9.6%)        | 4 (7.7%)         |       |
| 3                          | 18 (34.6%)      | 12 (23.1%)       |       |
| PET metabolic parameters   |                 |                  |       |
| SUV\textsubscript{max}     |                 |                  | 0.010*|
| Low                        | 21 (40.4%)      | 3 (5.8%)         |       |
| High                       | 14 (26.9%)      | 14 (26.9%)       |       |
| SUV\textsubscript{mean}    |                 |                  | 0.018*|
| Low                        | 22 (42.3%)      | 4 (7.7%)         |       |
| High                       | 13 (25%)        | 13 (25%)         |       |
| TLG                        |                 |                  | 0.237 |
| Low                        | 20 (38.5%)      | 6 (11.5%)        |       |
| High                       | 15 (28.8%)      | 11 (21.2%)       |       |
| MTV                        |                 |                  | 1.000 |
| Low                        | 18 (34.6%)      | 8 (15.4%)        |       |
| High                       | 17 (32.7%)      | 9 (17.3%)        |       |

*Significant at p < 0.05, **p < 0.01, ***p < 0.001.
and REACTOME_GLYCOLYSIS were associated with eIF6 expression (p.adjust < 0.05) (Fig. 2E). Moreover, we employed correlation analysis to screen glycolytic genes that are differentially expressed in eIF6 high and low expression groups, including GALK1, GOT1, GPC1, ENO2, GALM, G6PC, HK1, and GNPDA2 (Fig. 2F). We
further profiled the transcriptional expression and survival of the 8 significant genes in TCGA ESCA samples. Both GPC1 and GOT1 genes were upregulated in tumor tissues, and were implicated in poor ESCA prognosis (Fig. 2G, H, p < 0.05).

**Overexpression of eIF6 is associated with glucose metabolism in ESCA patients based on 18F-FDG PET-CT imaging**

To further investigate whether eIF6 influences tumor metabolism in ESCA, 18F-FDG PET/CT metabolic parameters were analyzed based on the eIF6 expression in 52 ESCC patients (Table 2). The SUV$_{\text{max}}$ and SUV$_{\text{mean}}$ were larger in ESCC patients with high eIF6 expression than in the low eIF6 expression group (p < 0.05). There was no significant statistical differences in TLG and MTV according to the eIF6 expression. Representative PET/CT images of ESCA patients with high (Fig. 3A) or low (Fig. 3B) SUV$_{\text{max}}$ are displayed. Patients with higher values of the primary lesion SUV$_{\text{max}}$ had higher expression of eIF6 and GLUT1, compared to those with lower SUV$_{\text{max}}$ values (p < 0.05, Fig. 3C, D). Besides, there was significant correlation between eIF6 protein levels and SUVmax, SUVmean or TLG (rho = 0.458, 0.460, and 0.300, respectively, p < 0.01, Fig. 4A, B, D). However, eIF6 intensity score showed no statistical correlation with MTV (Fig. 4C). These results demonstrated that eIF6 is associated with glucose metabolism in ESCA.

**Predictors of eIF6 expression in ESCA patients**

We next sought to determine the threshold of PET parameters that would predict tumor eIF6 status in primary ESCA. ROC curve analysis revealed a SUV$_{\text{max}}$ and SUV$_{\text{mean}}$ cutoff values of 18.2 and 10.52, respectively, which were related to AUC of 0.755 (sensitivity 76.5%, specificity 80.0%) and 0.736 (sensitivity 70.6%, specificity 77.1%) (Fig. 4E). Next, we analyzed the relationship between eIF6 and GLUT1 expression. The data showed a positive correlation between the immunohistochemistry scores of eIF6 and GLUT1 (rho = 0.453, p < 0.001, Fig. 4F).

**Suppression of eIF6 inhibits the ESCA cell proliferation and migration**

To explore the anti-tumor effect of eIF6 on human ESCA, we evaluated the eIF6 protein expression in four ESCA cell lines and a human epithelial cell line (HET1A). Compared with HET1A, there was higher expression of eIF6 in KYSE30, KYSE150, and Eca109 cells (Fig. 5A). Specific siRNAs were used to silence eIF6 in Eca109 and KYSE30 cells, and interfering efficiency was confirmed by qRT-PCR and Western blot analysis (Fig. 5B). We determined cell viability using both MTS assay (Fig. 5C) and EdU proliferation assay (Fig. 5D). The results showed that the cell viability of both siRNA (siEFl6) group was significantly lower than that of scramble siRNA control (siCtrl) group (p < 0.05).

It was evident from the FCM assay that treatment with eIF6 siRNA#1 induced a higher percentage of apoptotic cells as compared to those treated with control siRNA (Fig. 6A). In addition, wound healing assay demonstrated that treatment with eIF6 siRNA significantly inhibited migration of ESCA cell lines (Fig. 6B). To understand the potential mechanisms, we performed Western blot analysis. Unlike the siCtrl results in the Eca109 and KYSE30 cells, the eIF6 knockdown suppressed the expression of GLUT1 and Vimentin, a mesenchymal cytoskeletal marker, but promoted the expression of E-cadherin, an epithelial regulator, and Cyt c, which is a biochemical marker for apoptosis (Fig. 6C). These data suggest that eIF6 promotes ESCA cell proliferation and motility.

**The association between eIF6 and Tumor Immune Infiltration in ESCA**

We then assessed whether eIF6 expression was correlated with the characteristics of immune cells in ESCA. The xCell analysis revealed that the abundance of different types of lymphocytes such as, CD4$^+$ T cells (non-regulatory), CD4$^+$ T cells (Th1), Hematopoietic stem cell, NK cell, and stroma score was statistically different in the eIF6 high group and low group (p < 0.05, Fig. 7A). In sync, the lollipop plot of ssGSEA analysis showed that eIF6 expression was negatively correlated with the intensity of immunocytes, such as Tcm ($r = -0.388$, p < 0.001), NK cells ($r = -0.386$, p < 0.001), T helper cells ($r = -0.368$, p < 0.001), Macrophages ($r = -0.208$, p < 0.001), and CD8$^+$ T cells (p < 0.05). These results demonstrated that eIF6 is associated with immune cell infiltration in ESCA.

**Table 2** Comparison of PET metabolic parameter according to eIF6 expression

| PET metabolic parameter | eIF6—low (n = 35) | eIF6—high (n = 17) | p       |
|-------------------------|------------------|-------------------|---------|
| SUV$_{\text{max}}$ (mean±SD) | 14.46±7.69 | 20.3±7.45 | 0.012*  |
| SUV$_{\text{mean}}$ (mean±SD) | 8.18±4.06 | 11.59±4.47 | 0.008*  |
| TLG (median, range) | 21.98 (9.64–79.68) | 32.81 (18.59–163.81) | 0.095  |
| MTV (median, range) | 3.57 (1.98–8.63) | 3.74 (2.06–14.18) | 0.619  |
p = 0.008), T cells, Th2 cells, Th1 cells or iDCs, while positively correlated with the abundance of NK CD56 bright cells (r = 0.232, p = 0.003) and Th17 cells (r = 0.198, p = 0.011) (Fig. 7B). Besides, the violin plot indicated that the eIF6 high expression group had significantly lower B cells, T cells, NK cells, cytotoxic cells, mast cells, T helper cells, Th1 cells, and Th2 cells (p < 0.05, Fig. 7C).

**Association between eIF6 expression and immune marker sets in ESCA**

Further correlation analysis suggested that about half of the immunomodulators (chemokines, MHC-s, and immune stimulators) were negatively correlated with eIF6 in ESCA (Fig. 8A). There were no obvious differences in the correlation regardless of the tumor purity adjustment. Most marker sets of monocytes, TAMs and M2 macrophages exhibited significant correlation with eIF6 expression in both TIMER and GEPIA2 databases (p < 0.05, Table 3). Moreover, CD3E and CD2 of T cells, TBX21 and STAT4 of Th1 phenotype, BCL6, CD278 (ICOS) or CXCL13 of follicular T helper (Tfh) were negatively correlated with eIF6 expression in ESCA (p < 0.05, Table 4). According to the ssGSEA score of the gene sets, there was a negative correlation between
eIF6 and various immune checkpoints, such as TGFBR1 ($r = -0.300$), CSF1R ($r = -0.274$), PD-L2 (PDCD1LG2, $r = -0.238$), BTLA, CTLA4, CD96, TIGIT, HAVCR2, IL10, and VTCN1 in ESCA ($p < 0.05$, Fig. 8B). TIMER and GEPIA2 correlation analyses demonstrated that the immune marker genes of Treg and T cell exhaustion, such as CD25 (IL2RA), CTLA4, LAG3 and TIM-3 (HAVCR2) were significantly correlated with eIF6 expression in ESCA (Table 4). These findings were also observed in the GEPIA2 database. Similarly, eIF6 was negatively correlated with the immune signature of effector T cells ($r = -0.3$), exhausted T cells ($r = -0.23$), effector Treg T cells ($r = -0.22$), and Th1 like cells ($r = -0.22$) in ESCA (Fig. 8D). As illustrated in Fig. 8C, the protein level of CD45 and CD11b were enhanced in Eca109 cells after eIF6 knockdown, whereas the PD-L1 expression was not obviously affected as evident by the immunoblot analysis. Taken together, these findings suggested that eIF6 might participate in the immune responses and immune escape within the TME in ESCA.

### Discussion

The eukaryotic translation initiation factor eIF6 plays an essential role in cell growth and transformation, apoptosis, mitochondrial respiration, as well as lipogenic and glycolytic process [15, 21, 22, 36]. Although overexpression and oncogenic functions of eIF6 have been documented in other cancers, the role and biological functions of eIF6 in ESCA remains poorly understood. Herein, our results demonstrated that eIF6 was up-regulated both in ESCA tissues and cell lines, and high eIF6 expression led to poor prognosis in EA patients, with a favorable diagnostic reference value in ESCA. Moreover, knocked down of eIF6 significantly suppressed cell proliferation and migration, and induced cell apoptosis in the ESCA cells. The PET parameters have previously shown a remarkable potential for predicting gene expression status in cancers [37–39]. Our IHC analysis revealed that tumor eIF6 expression was positively correlated with FDG PET parameters in ESCA tissues. In addition, SUV$_{max}$ and SUV$_{mean}$ might act as suitable predictors of eIF6 expression in patients with ESCA. On the other hand, the bioinformatics analyses suggested that eIF6 is involved in metabolic pathways and tumor immune infiltration in
ESCA. These findings emphasize the oncogenic role of eIF6 and its therapeutic potential in the ESCA.

Our bioinformatics analyses demonstrated that high eIF6 expression predicted worse prognosis in ESCA patients. This was in sync with observations for human colorectal cancer, biliary tract cancer, hepatocellular carcinoma and lung adenocarcinoma [17, 19, 20, 40]. A previous study showed that eIF6 knockout mice impacted Myc-induced lymphomagenesis and tumor progression by modulating p53 [15]. Another study showed that high eIF6 expression is significantly associated with clinicopathological features, such as lymph node metastases in ovarian serous carcinoma [18]. Through IHC staining analysis, Gantenbein et al. [17] demonstrated significant differences in the eIF6 expression between higher and lower grade lung adenocarcinoma, but not in lung squamous cell carcinoma. In our study, eIF6 knockdown in ESCA cells inhibited cell migration via regulation of EMT marker genes. However, our data showed that eIF6 expression was not significantly associated with lymph node metastasis and p stages in ESCA tumors, probably due to different tumor-specific roles of eIF6 or small sample size.

Previously, Scagliola et al. [22] postulated that eIF6 depletion delays the liver disease progression from non-alcoholic fatty liver disease to hepatocellular carcinoma in vivo. Mechanistically, eIF6 depletion regulated mitochondrial respiration by targeting the mTORC1-eIF4F-YY1 translational axons. Cancer cells preferentially use aerobic glycolysis for stimulate ATP generation and lactate production (Warburg effect) [41]. Interestingly, inhibition of eIF6 could reduce cell growth by impairing lactate and ATP production in Malignant Pleural Mesothelioma [42]. Moreover, a previous systematic review demonstrated that eIF6 promoted glycolytic flux and fatty acid synthesis and increased tumor viability. But the mechanism through which mTOR or Myc regulate the activity of eIF6 need to be further investigated [43]. Our GSEA results

**Fig. 5** Silencing eIF6 expression inhibited the proliferation of ESCA cells. A Western blot analysis of eIF6 protein in normal epithelial cells (HET1A) and different ESCA cell lines. B qRT-PCR and Western blot analysis confirming the success of eIF6-siRNAs transfection. C Silencing of eIF6 expression reduced the growth of Eca109 and KYSE30 cells as revealed by MTS assays at 24, 48, and 72 h after transfection. D Cell proliferation decreased after eIF6-siRNAs treatment as detected by EdU staining. *p < 0.05, **p < 0.01, ***p < 0.001
demonstrated that the highly expressed eIF6 in ESCA patients regulated several metabolic pathways such as HALLMARK_MYC_TARGETS, HALLMARK_OXIDATIVE_PHOSPHORYLATION, REACTOME_GLYCOLYSIS, and KEGG_GLYCOLYSIS_GKCYCIBEIGENES. In recent years, $^{18}$F-FDG PET/CT has emerged as a non-invasive diagnostic tool for evaluating tumor glycolytic activity, diagnosing and staging of various malignant tumors [44, 45]. Molecular imaging can be applied to reveal the molecular profile of cancers [38, 46, 47]. This study found that high eIF6 expression was positively correlated with FDG uptake (in terms of SUV_{max} and SUV_{mean}) and the expression of GLUT1 in ESCA tissue. These results are in agreement with data from previous studies [12]. In addition, it was found that the SUV_{max} cutoff for PET/CT parameter was 18.2, which was more...
effective compared to the SUV\textsubscript{mean}, TLG, and MTV in predicting eIF6 expression. For these reasons, noninvasive methods, such as molecular imaging, could be used for predicting eIF6 status have great clinical relevance.

Evidence from previous studies has shown that immune cells or immune-related biomarkers in the TME can predict the survival outcomes and influence response to immune checkpoint therapy [48, 49]. By combining contrast-enhanced CT images and RNA-seq genomic data from tumour biopsies, Roger et al. demonstrated that imaging biomarker could be useful in estimating CD8 cell count and predicting clinical outcomes of patients treated with anti-PD-1 and PD-L1[49]. The dual roles of mutation burden and MS-indels was identified in predicting outcomes of central nervous system and synchronous cancers following immune checkpoint inhibitors (ICIs) treatment [50]. Thus, analysis of the cancer-specific immune biomarkers may reveal novel molecular targets for ESCA treatment. Here, using the xCell algorithm analysis, eIF6 was found to be negatively correlated with CD4+ T cells, hematopoietic stem cell, NK cell, T helper cells, macrophages, T cells, Th2 cells, Th1 cells, iDCs, among others. Moreover, the expression of eIF6 were negatively correlated with immune marker genes, such as genes of

![Image](Fig. 7 Immune characteristics between eIF6 high and low expression groups. A Tumor immune status of the high (n = 81) and low eIF6 expression groups (n = 81) using xCell microenvironment scores in the TCGA datasets. B Lollipop plot showing the correlation between the relative abundance of immune cells and eIF6 gene expression levels in the TCGA-ESCA samples determined using the ssGSEA method. C Violin plot displaying differences in 13 immune cell types between low and high eIF6 expression groups. *p < 0.05, **p < 0.01, ***p < 0.001)
monocytes, TAMs, M2 macrophages, T cell, Th1, and Th17 phenotype. These results demonstrate that eIF6 expression may be negatively correlated with immune cells including macrophages, T cells, and Th1 cells. We subsequently verified that showed that eIF6 silencing increased the expression of macrophage markers CD45 and CD11b in ESCA cells. Previous studies suggested that cancer cells also acquired immune regulatory membrane proteins such as PD-L1, CD4, CD45, CTLA4 and Tim3 expressed in lymphocytes, which in turn contribute to the development of the immunosuppressive tumor microenvironment [51–53]. Whether CD45 or CD11b-positive cancer cells could regulate the ESCA tumor microenvironment remains further exploration. Consistently, a previous study revealed that eIF6 overexpression increases the number of activated T cells [16, 25]. Moreover, eIF6 overexpression induced the metabolic switch in CD4+ T cells [26],

Fig. 8 Correlation between eIF6 expression and immune-related genes in human ESCA. A A heatmap showing the spearman's rank correlation between eIF6 expression level and immunostimulators, MHC genes, chemokines, and immunoinhibitors B based on the TISIDB database. Positive and negative correlation are indicated by red and blue, respectively. C Western blot analysis for CD45, CD11b, and PD-L1 in Eca109 cells with eIF6 knockdown. D Scatter plots showing the correlation between immune cells infiltrations and the eIF6 expression using GEPIA2 database. *p < 0.05, **p < 0.01.
and was negatively correlated with most immunomodulators (chemokines, MHC-s, immune stimulators) in ESCA. Similarly, we found a negative correlation between eIF6 expression and immune checkpoints, including CTLA4, and HAVCR2, in ESCA. It has been reported that CTLA4 activates CD4+ and CD8+ T cells, whereas TIM-3 functions as a negative regulator of T cell activation and also involved in exhaustion, Th1 responses [54, 55]. Inhibitors of CTLA4 and TIM-3 can be applied as immunotherapeutic targets in the treatment of cancer patients [56, 57]. This suggests that eIF6 might serve as a potential biomarker of immune cell infiltration in ESCA.

There are several limitations to this study. First, although we found that high expression of eIF6 was associated with poor prognosis of ESCA patients, this finding was not experimentally validated using clinical samples. Second, although metabolic and genomic signatures were combined to investigate potential biomarkers and mechanisms, more samples and additional validation studies were needed. Third, further in-depth clinical research should be conducted to clarify the functional role of eIF6 in the tumor immunosuppressive microenvironment.

Table 3 Correlation analysis between eIF6 and relate genes and markers of innate immunity cells in ESCA

| Description       | Genemarkers | TIMER (n = 184) | GEPIA2 (n = 181) |
|-------------------|-------------|----------------|------------------|
|                   | Purity      | None           |                  |
|                   | Cor         | p              | Cor             | p              |
| Monocyte          | CD14        | −0.154 *       | −0.132 0.073     | −0.094 0.210   |
|                   | CD86        | −0.286 *       | −0.262 *         | −0.230 *       |
|                   | CD16 (FCGR3A)| −0.238 *       | −0.223 *         | −0.190 *       |
| TAM               | CD68        | 0.139 0.062    | 0.156 *         | 0.140 0.061    |
|                   | CCL2        | −0.266 *       | −0.262 *         | −0.130 0.077   |
|                   | CCL5        | −0.117 0.116   | −0.125 0.090     | −0.081 0.280   |
| M1 Macrophage     | INOS (NOS2) | 0.137 0.066    | 0.129 0.080      | 0.160 *        |
|                   | CXCL10      | −0.129 0.083   | −0.121 0.101     | −0.018 0.800   |
|                   | TNF-α (TNF)| −0.029 0.695   | −0.008 0.913     | −0.028 0.710   |
| M2 Macrophage     | CD206 (MRC1)| −0.203 *       | −0.200 *         | −0.150 *       |
|                   | CD163       | −0.208 *       | −0.199 *         | −0.094 0.210   |
|                   | IL10        | −0.177 *       | −0.182 *         | −0.150 *       |
| Neutrophils       | CD66b (CEACAM8) | 0.142 0.057   | 0.113 0.127      | 0.001 0.980   |
|                   | CD11b (ITGAM) | −0.189 *      | −0.166 *         | −0.170 *       |
|                   | CCR7        | −0.039 0.601   | −0.059 0.427     | −0.180 *       |
|                   | CD15 (FUT4) | 0.085 0.256    | 0.071 0.340      | 0.110 0.160   |
| Natural killer cell| KIR2DL1    | 0.052 0.486    | 0.041 0.584      | −0.090 0.230  |
|                   | KIR2DL3     | −0.167 *       | −0.159 *         | −0.091 0.220   |
|                   | KIR2DL4     | 0.037 0.625    | 0.035 0.633      | −0.025 0.740   |
|                   | KIR3DL1     | 0.022 0.766    | 0.013 0.858      | −0.095 0.200   |
|                   | KIR3DL2     | −0.107 0.153   | −0.107 0.147     | −0.029 0.700   |
|                   | KIR3DL3     | −0.001 0.993   | 0.003 0.963      | −0.048 0.520   |
|                   | KIR2DS4     | 0.041 0.586    | 0.053 0.470      | −0.095 0.200   |
| Dendritic cell    | HLA-DPB1    | −0.163 *       | −0.165 *         | −0.210 *       |
|                   | HLA-DQB1    | −0.078 0.294   | −0.093 0.210     | −0.096 0.200   |
|                   | HLA-DRA     | −0.129 0.083   | −0.136 0.065     | −0.110 0.130   |
|                   | HLA-DPA1    | −0.137 0.065   | −0.138 0.061     | −0.130 0.070   |
|                   | BDCA-1 (CD1C)| −0.250 *       | −0.249 *         | −0.250 *       |
|                   | BDCA-4 (NRP1)| −0.213 *      | −0.215 *         | −0.100 0.170   |
|                   | CD11c (ITGAX)| −0.178 *      | −0.168 *         | −0.210 *       |
|                   | NKp46 (NCR1)| −0.031 0.681   | −0.045 0.547     | −0.100 0.170   |

TAM, tumor associated macrophage; Cor, R value of Spearman's correlation. Purity, correlation adjusted by purity. *p < 0.05. None, correlation without adjustment
In conclusion, this study shows that eIF6 is highly expressed in ESCA tumor tissues and could predict worse prognosis. Regarding biological functions, we demonstrated that eIF6 expression influenced preoperative FDG uptake and involved in immune cell infiltration in ESCA, which provides novel insights to the tumor biology. eIF6 is likely to be a prognostic biomarker for ESCA. Further prospective experiments should be carried out to verify the expression and function of eIF6 in ESCA.

**Abbreviations**
eIF6: Eukaryotic initiation factor 6; TCGA: The Cancer Genome Atlas; ESCA: Esophageal carcinoma; EA: Esophageal adenocarcinoma; ESCC: Esophageal squamous cell carcinoma; IHC: Immunohistochemical; GLUT1: Glucose transporter-1; 18F-FDG-PET: 18F-fluorodeoxyglucose positron emission tomography; CT: Computed tomography; SUVmax: Maximum standardized uptake value; ROI: Region of interest; MTV: Metabolic tumor volume; TLG: Total lesion glycolysis; OS: Overall survival; ROC: Receiver operating characteristic; AUC: Area under curve; HET1A: Human epithelial cell line; NPM1: Nucleophosmin 1;
EF2S2: Eukaryotic translation initiation factor 2 Subunit β, METTL3: Methyltransferase 3, TME: Tumor microenvironment, PD-1: Programmed death-1, PD-L1: Programmed death ligand-1, CTLA4: Cytotoxic T lymphocyte associated antigen 4, Cyt c: Cytochrome c, G0: Gene ontology, REEG: Kyoto Encyclopedia of Genes and Genomes, GSEA: Gene Set Enrichment Analysis, PPI: Protein–protein interaction; STRING: Search Tool for the Retrieval of Interacting Genes/ Proteins; TIMER: The Tumor Immune Estimation Resource; GSEA: Gene set variation analysis; TISIDB: Tumor Immune System Interactions; siRNA: Small interfering RNA.

Author contributions

YG, CBK and ZJP designed the study, interpreted the results. YG, LLY, and JZ performed the histological examination, and contributors in writing the manuscript. FLY, HXJ, and FT, collected the clinical information and conducted data analysis. XSL, HBW, XYX, and XYL were responsible for the collection and assembly of bioinformatics data. All authors read and approved the final manuscript.

Funding

This work was supported by National Natural Science Foundation of China (No. 81971060); the Hubei province’s Outstanding Outstanding Medical Academic Leader program, the Foundation for Innovative Research Team of Hubei Provincial Department of Education (No. T2020025), the general project of Hubei Provincial Department of Education (No. B202116), Innovative Research Program for Graduates of Hubei University of Medicine (No. YC2020011 and YC2021018) and the Key Discipline Project of Hubei University of Medicine.

Declarations

Ethics approval and consent to participate

The study was approved by the biomedical ethics committee of the Ethics Committee of Taihe Hospital.

Competing interests

The authors declare that they have no competing interests.

Author details

1Department of Nuclear Medicine and Institute of Anesthesiology and Pain, and Department of Pathology, Taihe Hospital, Hubei University of Medicine, No. 32, Renmin Road, Shiyan 442000, China. 2 Hubei Key Laboratory of Embryonic Stem Cell Research, Shiyan 442000, China.

Received: 28 February 2022 Accepted: 24 June 2022 Published online: 06 July 2022

References

1. Frankel AM, Jammula S, Li X, Contino G, Killcoyne S, Abbas S, Perner J, Bower L, Devonshire G, Ococks E, et al. The landscape of selection in 551 esophageal adenocarcinomas defines genomic biomarkers for the clinic. Nat Genet. 2019;51:506–16.

2. Lordick F, Janjigian YY. Clinical impact of tumour biology in the management of gastroesophageal cancer. Nat Rev Clin Oncol. 2016;13:348–60.

3. Krause BJ, Herrmann K, Wieder H, Zum Buschenfelde CM. 18F-FDG PET and 18F-FDG PET/CT for assessing response to therapy in esophageal cancer. J Nucl Med. 2009;50:985–95.

4. de Geus-Oei L, Krieken JHJM, Aliredjo RP, Krabbe PFM, Frielink C, Verhagen C. The role of immune system cell subpopulations and on thymocyte maturation. Data Brief. 2020;25:1051–8.

5. Hofheinz F, Li Y, Steffen IG, Lin Q, Lili C, Hua W, van den Hoff J, Zscheischler S. Confirmation of the prognostic value of pretherapeutic tumor SUR and MTV in patients with esophageal squamous cell carcinoma. Eur J Nucl Med Mol. 2019;46(1):91–9.

6. Lim GH, Park YJ, Shin M, Cho YS, Choi JY, Lee KH, Hyun SH. Tumor SUVs on 18F-FDG PET/CT and Aggressive Pathological Features in Esophageal Squamous Cell Carcinoma. Clin Nucl Med. 2020;45:8.

7. Antonicov L, Gallivanova F, Sollini M, Sagona A, Invento A, Manfrinati G, Kirenko M, Tinterrri C, Chiti A, Castiglioni I. [18F]FDG PET/CT features for the molecular characterization of primary breast tumors. Eur J Nucl Med Mol. 2017;44(1):1945–54.

8. Brenner W, Friedrich RE, Gavid KA, Hagel C, von Deimling A, de Witt M, Buchert R, Clausen M, Mautner VF. Prognostic relevance of FDG PET in patients with neurofibromatosis type-1 and malignant peripheral nerve sheath tumours. Eur J Nucl Med Mol. 2006(33):428–32.

9. Chen R, Zhou X, Liu J, Huang G. Relationship 18F-FDG PET/CT Findings and HER2 Expression in Gastric Cancer. J Nucl Med. 2016;57:1040–4.

10. Zhou L, Luan Y, Gao L, Yu X, Dai Q, Yang J, Pei Z. Nucleoplasmin 1 over-expression correlates with 18F-FDG PET/CT metabolic parameters and improves diagnostic accuracy in patients with lung adenocarcinoma. Eur J Nucl Med Mol. 2021;48(8):904–12.

11. Yang JW, Yuan LL, Gao Y, Liu XS, Wang YJ, Zhou LM, Ku YJ, Li XH, Ke CB, Pei ZJ. [18F]FDG PET/CT metabolic parameters correlate with EF2S2 expression status in colorectal cancer. J Cancer. 2021;12:5838–47.

12. Liu X, Yuan L, Gao Y, Zhou L, Yang J, Pei Z. Overexpression of METTL3 associated with the metabolic status on 18F-FDG PET/CT in patients with Esophageal Carcinoma. J Cancer. 2020;11:4851–60.

13. Weis F, Giudice E, Churcher M, Jin L, Hilcenko C, Wong CC, Traylor D, Kay RR, Warren AJ. Mechanism of elf6 release from the nascent 60S ribosomal subunit. Nat Struct Mol Biol. 2015;22:914–9.

14. Brina D, Grosso S, Miluzio A, Biffo S. Translational control by 80S formation and 60S availability: The central role of elf6, a rate limiting factor in cell cycle progression and tumorigenesis. Cell Cycle. 2014;10:3441–6.

15. Gandin V, Miluzio A, Barbieri AM, Beugnt A, Kiyokawa H, Marchisio PC, Biffo S. Eukaryotic initiation factor 6 is rate-limiting in translation, growth and transformation. Nature. 2008;455:684–8.

16. Miluzio A, Beugnt A, Grosso S, Brina D, Mancino M, Campaner S, Amati B, de Marco A, Biffo S. Impairment of Cytoplasmic elf6 activity restricts lymphomagenesis and tumor progression without affecting normal growth. Cancer Cell. 2011;19:765–75.

17. Gentenbein N, Bernhardt E, Anders J, Golob-Swirzl N, Krassing S, Wiedle C, Briner L, Lindenmann J, Fink-Neuboeck N, Gollovitsch F, et al. Influence of eukaryotic translation initiation factor 6 on non-small cell lung cancer development and progression. Eur J Cancer. 2018;101:165–80.

18. Flavin RJ, Smyth PC, Finn SP, Laio O, O’Toole SA, Barrett C, Ring M, Denning KM, Li J, Aherne ST, et al. Altered elf6 and Dicer expression is associated with clinicopathological features in ovariian serous carcinoma patients. Mod Pathol. 2008;21:676–84.

19. Lin J, Yu X, Xie L, Wang P, Li T, Xiao Y, Zhou J, Peng S, Huang J, Luo Y, et al. elf6 Promotes colorectal cancer proliferation and Invasion by regulating AKT-Related Signaling Pathways. J Biomed Nanotechnol. 2019;15:1556–67.

20. Sun L, Liu S, Wang X, Zheng X, Chen Y, Shen H. elf6 promotes the malignant progression of human hepatocellular carcinoma via the mTOR signaling pathway. J Transl Med. 2021;19:198.

21. Brina D, Miluzio A, Ricciardi S, Clarke K, Davidisen PK, Viero G, Tebaldi T, Olfenhäuser N, Rozman J, Rathkolb B, et al. Targeting of elf6-driven translation induces a metabolic rewiring that reduces NAFLD and the consequent evolution to hepatocellular carcinoma. Nat Commun. 2021;12:128.

22. Scagliola A, Miluzio A, Ventura G, Soltero S, Cordiglieri C, Manfrini N, Cirino D, Ricciardi S, Valenti L, Baselli G, et al. Targeting of elf6-driven translation improves diagnostic accuracy in patients with lung adenocarcinoma. Eur J Nucl Med Mol. 2021;48(8):904–12.

23. Li Y, Lu Z, Che Y, Wang J, Sun S, Huang J, Mao S, Lei Y, Chen Z, He J. Immune signature profiling identified predictive and prognostic factors for esophageal squamous cell carcinoma. Oncol Transl. 2017;6:e1556147.

24. Baba Y, Nomoto D, Okadome K, Ishimoto T, Iwasaki M, Miyamoto Y, Yoshida N, Baba H. Tumor immune microenvironment and immune checkpoint inhibitors in esophageal squamous cell carcinoma. Cancer Sci. 2020;111:3132–41.

25. Manfrini N, Ricciardi S, Miluzio A, Fedeli M, Scagliola A, Gallo S, Adler T, Busch DH, Gailus-Durner V, Fuchs H, et al. On the effects of elf6 downmodulation on the proportions of innate and adaptive immune system cell subpopulations and on thymocyte maturation. Data Brief. 2017;14:653–6.

26. Golub-Schwartz N, Puchas P, Gogg-Kamerer M, Weichert W, Göppert B. New Pancreatic Cancer Biomarkers elf5, elf7, elf3 and elf6 Play a Major Role in Translational Control in Ductal Adenocarcinoma. Anticancer Res. 2020;40:3109–18.
27. Lau CM, Adams NW, Geary CD, Weizman O, Rapp M, Pritykin Y, Leslie CS, Sun JC. Epigenetic control of innate and adaptive immune memory. Nat Immunol. 2018;19:963–72.

28. Byun DJ, Wolchok JD, Rosenberg LM, Girotra M. Cancer immunotherapy—immune checkpoint blockade and associated endocrinopathies. Nat Rev Endocrinol. 2017;13:195–207.

29. Sanchez-Vega F, Mina M, Armenia J, Chatila WK, Luna A, La KC, Dimitriadis S, Liu DL, Kantheti HS, Saghafinia S, et al. Oncogenic signaling pathways in the cancer genome atlas. Cell. 2018;173:321–37.

30. Sankaya I, Sankaya A. Assessing PET Parameters in Oncologic 18F-FDG Studies. J Nucl Med Technol. 2020;48:278–82.

31. Velasquez LM, Boelaart R, Kolla G, Hayes W, Hoekstra OS, Lammertstma AA, Gallbrath SM. Repeatability of 18F-FDG PET in a Multicenter Phase I study of patients with advanced gastrointestinal malignancies. J Nucl Med. 2009;50:1646–54.

32. Nagy D, Munkácsy G, Gyffrty P. Pancancer survival analysis of cancer hallmark genes. Sci Rep-Uk. 2020;11:6047.

33. Haneltmann S, Castelo R, Guinnrey J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics. 2013;14:7.

34. Bindea G, Mlecnik B, Tosolini M, Kirilovsky A, Waldner M, Obenauf AC, Sanderson S, Biermann A, Hockel M, et al. Establishment of a reference ovarian tumor sample set for immune infiltration analysis. BMC Bioinformatics. 2012;13:22.

35. Ru B, Ngar WC, Tong Y, Zhong JY, Zhong S, Wu WC, Chu KC, Yiu WC, Ying K, et al. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study. Lancet Oncol. 2018;19:1180–91.

36. Das A, Sudhaman S, Morgenstern D, Coblenz A, Chung J, Stone SC, Alsafwani N, Liu ZA, Karsaneh OAA, Soleimani S, et al. Genomic predictors of response to PD-1 inhibition in children with germline DNA replication repair deficiency. Nat Med. 2022;28:125–35.

37. Zheng H, Cui Y, Li X, Du B, Li Y. Prognostic Significance of 18F-FDG PET/CT in Gastric Cancer. Int J Mol Sci. 2020;21:4105.

38. Toledano MN, Desbordes P, Banjar A, Gardin I, Vera P, Ruminy P, Jardin F, Angell H, Fredriksen T, Lafontaine L, Berger A, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity. 2013;39:782–95.

39. Lee SH, Ha S, An HJ, Lee JS, Han W, Im S, Ryu HS, Kim WH, Chang JM, Cho SW, et al. Combination of baseline FDG PET/CT total metabolic index and TILs quantification by threshold-independent method for the prediction of early relapse in patients with resected colorectal cancer. Gut. 2017;66:463–73.

40. Han Y, Liu Q, Hou J, Gu Y, Zhang Y, Chen Z, Fan J, Zhou W, Qiu S, Zhang Y, et al. Tumor-induced generation of splenic erythroid-like ter-cells promotes tumor progression. Cell. 2018;173:634–48.

41. Tu L, Guan R, Yang H, Zhou Y, Hong W, Ma L, Zhao Y, Yu M. Assessment of the expression of the immune checkpoint molecules PD-1, CTLA4, TIM-3 and LAG-3 across different cancers in relation to treatment response, tumor-infiltrating immune cells and survival. Int J Cancer. 2020;147:423–39.

42. Ngjow SF, van Schiedt B, Akiba H, Yagita H, Teng MW, Smyth MJ, Anti-TIM3 Antibody Promotes T Cell IFN-γ-mediated antitumor immunity and suppresses established tumors. Cancer Res. 2011;71:3940–51.

43. Sugawara I, Kawai M, Ito H, Tanaka M, Seto Y, Todo T. Oncolytic herpes virus G47Δ works synergistically with CTLA-4 inhibition via dynamic intratumoral immune modulation. Molecular Therapy - Oncolytics. 2020;12:129–42.

44. Sabatos CA, Chakravarti S, Cha E, Schubart A, Sánchez-Fueyo A, Zheng XX, Coyle AJ, Strom TB, Freeman GJ, Kuchroo VK. Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance. Nat Immunol. 2003;4:1102–10.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions